1. Search Result
Search Result
Results for "

inflammatory pain disorders

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0576
    Solanesol
    2 Publications Verification

    Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP Neurological Disease Metabolic Disease Inflammation/Immunology
    Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .
    Solanesol
  • HY-12152
    PNU-120596
    1 Publications Verification

    NSC 216666

    nAChR Neurological Disease Inflammation/Immunology
    PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) that can cross the blood-brain barrier, with an EC50 of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research .
    PNU-120596
  • HY-B1018A
    Phenelzine sulfate
    Maximum Cited Publications
    6 Publications Verification

    Monoamine Oxidase GABA Receptor Histone Demethylase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
    Phenelzine sulfate
  • HY-13985

    Sodium Channel Neurological Disease Inflammation/Immunology
    Nav1.7 inhibitor (compound II), a sulfonamide, is a potent Nav1.7 inhibitor. Nav1.7 inhibitor has the potential for a wide range of disorders, particularly pain, including acute pain, inflammatory pain and/or neuropathic pain .
    Nav1.7 inhibitor
  • HY-136362

    c-Fms Inflammation/Immunology Cancer
    ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers .
    ARRY-382
  • HY-147306

    NO Synthase Neurological Disease
    ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation .
    ZLc-002
  • HY-B1018AS

    Isotope-Labeled Compounds Monoamine Oxidase GABA Receptor Histone Demethylase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
    Phenelzine-d5 sulfate
  • HY-137090

    BP 2.94

    Histamine Receptor Neurological Disease
    BP 2-94 (BP 2.94) is an orally active and highly selective prodrug targeting the histamine H3 receptor. BP 2-94 exerts anti-inflammatory, analgesic and antinociceptive effects by inhibiting histamine release and modulating neurogenic inflammation. BP 2-94 is promising for research of asthma, migraines, and inflammatory pain-related disorders .
    BP 2-94
  • HY-174846

    Cannabinoid Receptor TRP Channel Drug Intermediate Neurological Disease Inflammation/Immunology
    TRPM8 antagonist 4 prodrug (Compound 8b) is an orally active CB2R agonist (EC50: 51.2 nM) and a weak TRPM8 antagonist. TRPM8 antagonist 4 prodrug is a prodrug of TRPM8 antagonist 4 (HY-174825). TRPM8 antagonist 4 prodrug exhibits anti-inflammatory and analgesic activities and can be used in the research of inflammation-related pain disorders .
    TRPM8 antagonist 4 prodrug
  • HY-N0576R

    Reference Standards Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP Neurological Disease Metabolic Disease Inflammation/Immunology
    Solanesol (Standard) is the analytical standard of Solanesol (HY-N0576). This product is intended for research and analytical applications. Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .
    Solanesol (Standard)
  • HY-167734

    AY-30715

    COX Inflammation/Immunology
    Pemedolac (AY-30715) is a potent analgesic with significant pain-relief efficacy against chemically induced and inflammatory pain in animal models. Pemedolac displays a notable separation between analgesic effects and anti-inflammatory activity, achieving effective pain relief at much lower doses than those required for anti-inflammatory or gastric irritant effects. Pemedolac also shows low ulcerogenic potential, indicating a safer profile compared to standard NSAIDs while being utilized for the treatment of neurological, skin, and musculoskeletal disorders.
    Pemedolac
  • HY-151621

    Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.4 μM .
    sEH inhibitor-13
  • HY-W011340

    Drug Metabolite Endogenous Metabolite Inflammation/Immunology
    5-Hydroxy flunixin, the principal metabolite of Flunixin (HY-121046), retains the Flunixin's anti-inflammatory properties and plays a significant role in mitigating pain and inflammation in various veterinary applications. It assists in alleviating conditions such as colic in horses, musculoskeletal disorders, and infectious diseases in cattle, while also supporting the management of mastitis-metritis-agalactia syndrome in sows.
    5-Hydroxy flunixin
  • HY-W011340R

    Endogenous Metabolite Reference Standards Inflammation/Immunology
    5-Hydroxy flunixin (Standard) is the analytical standard of 5-Hydroxy flunixin. This product is intended for research and analytical applications. 5-Hydroxy flunixin, the principal metabolite of Flunixin (HY-121046), retains the Flunixin's anti-inflammatory properties and plays a significant role in mitigating pain and inflammation in various veterinary applications. It assists in alleviating conditions such as colic in horses, musculoskeletal disorders, and infectious diseases in cattle, while also supporting the management of mastitis-metritis-agalactia syndrome in sows.
    5-Hydroxy flunixin (Standard)
  • HY-170994

    Imidazoline Receptor Neurological Disease Inflammation/Immunology
    I2-IRs ligand-1 (Compound 12d) is an orally active and BBB-penetrable compound. I2-IRs ligand-1 has a high affinity for imidazoline I2 receptors (I2-IRs) (pKi: 9.98). I2-IRs ligand-1 can improve cognitive impairment in senescent mice and exhibits analgesic, anti-inflammatory, and neuroprotective activities. I2-IRs ligand-1 can be used for the research of Alzheimer's disease and related pain disorders .
    I2-IRs ligand-1
  • HY-186059

    Potassium Channel Neurological Disease
    HCN2 modulator-4 is a HCN2 ion channel inhibitor. HCN2 modulator-4 inhibits HCN2 ion channel activity. HCN2 modulator-4 can be used for the research of pain, inflammatory pain, neuropathic pain, tinnitus, central nervous system disorders, psychiatric disorders, mood disorders .
    HCN2 modulator-4
  • HY-186059A

    Potassium Channel Neurological Disease
    HCN2 modulator-5 (S-configuration 39) is a HCN2 ion channel inhibitor. HCN2 modulator-5 inhibits HCN2 ion channel activity. HCN2 modulator-5 can be used for the research of pain, inflammatory pain, neuropathic pain, tinnitus, central nervous system disorders, psychiatric disorders, mood disorders .
    HCN2 modulator-5
  • HY-186060

    HCN Channel Neurological Disease
    HCN2 modulator-6 is a HCN2 ion channel inhibitor has an IC50 of 7 nM. HCN2 modulator-6 inhibits HCN2 ion channel activity. HCN2 modulator-6 can be used for the research of pain, inflammatory pain, neuropathic pain, tinnitus, central nervous system disorders, psychiatric disorders, mood disorders .
    HCN2 modulator-6
  • HY-171894

    Biochemical Assay Reagents Neurological Disease Inflammation/Immunology
    AXSP0056BS is an allosteric GTP cyclohydrolase I (GCH1) inhibitor with an IC50 of 4 μM. AXSP0056BS is applicable to the research of neuropathic and inflammatory pain disorders .
    AXSP0056BS
  • HY-15026

    Endogenous Metabolite Inflammation/Immunology
    ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation .
    ATB 429
  • HY-186058

    HCN Channel Neurological Disease Inflammation/Immunology
    HCN2-IN-6 is a HCN2 ion channel inhibitor with an IC50 of 7 nM. HCN2-IN-6 shows weak inhibitory activity for HCN4. HCN2-IN-6 can be used for the research of inflammatory disease and neurological disorders .
    HCN2-IN-6
  • HY-186057

    HCN Channel
    HCN2-IN-5 is a HCN2 ion channel inhibitor with an IC50 of 9 nM. HCN2-IN-5 shows weak inhibitory activity for HCN4. HCN2-IN-5 can be used for the research of inflammatory disease and neurological disorders .
    HCN2-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: